To better understand the role of ROS release in in-activation of AKT, we pre–treated DLBCL cells with 10mM NAC for 2 hours followed by treatment with Resveratrol for 24 hours. The gene discussed is AKT1; the disease is diffuse large B-cell lymphoma.